News

Teitur Trophics receives Eurostars funding to support pipeline project in hearing loss

5 Feb at 10:19 am

We are thrilled to announce that Teitur has received a Eurostars grant for the project Breakthrough Regenerative Peptide Therapy to Cure Patients with Sensorineural Hearing Loss (RE-HEAR). The RE-HEAR project is a collaboration between…

Sejelas Founder-CEO Interview with Simon Mølgaard

September 26, 2024

Our CEO Simon Mølgaard was interviewed by Sejelas where he talks about Teitur Trophics and our commitment to developing novel treatments for treating patients suffering from neurodegenerative diseases. You can read the full interview…

Teitur Trophics receives grant from Innobooster to support biomarker development

July 9, 2024

We are thrilled and honored to announce that Teitur has received a grant from Innobooster to support our groundbreaking work on identifying novel biomarkers for treating Huntington’s Disease (HD). This funding will propel our…

Teitur Trophics ApS become part of Incuba Skejby

April 29, 2024

We are very happy to become a part of the great innovative environment at Incuba Skejby, where we are able to develop and grow in our new offices and laboratories. Read more on the…

Teitur Trophics has been nominated for EY Entrepreneur of The Year – Life Sciences

October 31, 2023

The team at Teitur are extremely honoured to have been nominated for EY Entrepreneur of The Year – Life Sciences. The nomination recognizes the development the company has gone through since starting in 2020.…

Teitur Trophics has been nominated for European Lifestars Award – Series A: Finance raise of the year

October 6, 2023

We are excited to be nominated for European Lifestars Award – Series A: Finance raise of the year. The nomination is a testament to the incredible team at Teitur Trophics and our ambition and…

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

March 14, 2023

Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest
Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases
First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study

Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The…

News

Teitur Trophics receives Eurostars funding to support pipeline project in hearing loss

Sejelas Founder-CEO Interview with Simon Mølgaard

Teitur Trophics receives grant from Innobooster to support biomarker development

Teitur Trophics ApS become part of Incuba Skejby

Teitur Trophics has been nominated for EY Entrepreneur of The Year – Life Sciences

Teitur Trophics has been nominated for European Lifestars Award – Series A: Finance raise of the year

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest

Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases

First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study

Teitur Trophics receives Innobooster grant to develop candidate towards IND

Teitur Trophics closes convertible loan from Sunstone

Teitur Trophics receives Innobooster grant from Innovation Fund Denmark for advancing HD program

Latest News

Contacts